Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this two-stage phase II study is to assess the efficacy of BKM120, as measured
by determining the progression free survival (PFS), in patients with pretreated metastatic
Non-small Cell Lung Cancer (NSCLC) that exhibits PI3K pathway activation. BKM120 will be
investigated in two groups of NSCLC patients according to the histology of the cancer:
squamous and non-squamous.